search
Back to results

HPV Prevalence in Transpersons - a Prospective Study

Primary Purpose

Papillomavirus Infection, Transsexualism

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Colli-Pee urine collection device
Survey
Sponsored by
Sophie Pils
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Papillomavirus Infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Transpeople
  • Age over 18 years
  • Sufficient knowledge of German

Exclusion Criteria:

  • Age under 18 years
  • Insufficient knowledge of German

Sites / Locations

  • Medical University of Vienna
  • Institute of Microbiology and Immunology Faculty of Medicine

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Transpeople

Arm Description

1x urine sampling for HPV analysis 1x survey

Outcomes

Primary Outcome Measures

HPV prevalence in transpeople
HPV prevalence in transpeople

Secondary Outcome Measures

Full Information

First Posted
April 25, 2021
Last Updated
March 13, 2023
Sponsor
Sophie Pils
search

1. Study Identification

Unique Protocol Identification Number
NCT04864951
Brief Title
HPV Prevalence in Transpersons - a Prospective Study
Official Title
HPV Prevalence in Transpersons - a Prospective Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
May 2, 2021 (Actual)
Primary Completion Date
November 1, 2021 (Actual)
Study Completion Date
November 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Sophie Pils

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In this study, Human Papilloma Virus (HPV) prevalence will be determined once in the urine of 200 trans people. In addition, subjects will be asked to complete a questionnaire about their sexual orientation, which is adapted from the largest published study.
Detailed Description
All transpeople who visit the outpatient clinic are asked to participate in the study. After being informed and signing the Informed Consent Form, the subjects are asked to give first-void urine and fill out the survey. The urine samples are sent pseudonymously to the University of Ljubljana for analysis. The subjects will be informed about their results within 3 weeks.If the result is positive, the subjects will be offered voluntary further care in our HPV outpatient clinic. However, this will take place outside the study. The data collected there can be used for further analyses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Papillomavirus Infection, Transsexualism

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
203 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Transpeople
Arm Type
Other
Arm Description
1x urine sampling for HPV analysis 1x survey
Intervention Type
Diagnostic Test
Intervention Name(s)
Colli-Pee urine collection device
Intervention Description
first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.
Intervention Type
Other
Intervention Name(s)
Survey
Intervention Description
Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking
Primary Outcome Measure Information:
Title
HPV prevalence in transpeople
Description
HPV prevalence in transpeople
Time Frame
one year

10. Eligibility

Sex
All
Gender Based
Yes
Gender Eligibility Description
all study participants classify themselves as transmen, transwomen, genderqueer, non-binary or other gender identity
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Transpeople Age over 18 years Sufficient knowledge of German Exclusion Criteria: Age under 18 years Insufficient knowledge of German
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elmar Joura, MD
Organizational Affiliation
Medical University of Vienna, Department of Obstetrics and Gynecology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of Vienna
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Institute of Microbiology and Immunology Faculty of Medicine
City
Ljubljana
ZIP/Postal Code
1000
Country
Slovenia

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29538411
Citation
Reisner SL, Deutsch MB, Peitzmeier SM, White Hughto JM, Cavanaugh TP, Pardee DJ, McLean SA, Panther LA, Gelman M, Mimiaga MJ, Potter JE. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients. PLoS One. 2018 Mar 14;13(3):e0190172. doi: 10.1371/journal.pone.0190172. eCollection 2018.
Results Reference
background
PubMed Identifier
36263396
Citation
Pils S, Mlakar J, Poljak M, Domjanic GG, Kaufmann U, Springer S, Salat A, Langthaler E, Joura EA. HPV screening in the urine of transpeople - A prevalence study. EClinicalMedicine. 2022 Oct 12;54:101702. doi: 10.1016/j.eclinm.2022.101702. eCollection 2022 Dec.
Results Reference
derived

Learn more about this trial

HPV Prevalence in Transpersons - a Prospective Study

We'll reach out to this number within 24 hrs